{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.0","upperLimit":"130.0","value":"111.0"},{"groupId":"OG001","lowerLimit":"85.0","upperLimit":"225.0","value":"112.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Duration of time from start of study treatment to date of disease progression or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Assigned to 60 mg dose, 6 doses/cycle","id":"OG000","title":"Selinexor (PTCL)"},{"description":"Assigned to 60 mg dose, 6 doses/cycle (6 patients); assigned to 60 mg dose, 8 doses/cycle (1 patient)","id":"OG001","title":"Selinexor (CTCL)"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat population.","reportingStatus":"POSTED","timeFrame":"Study treatment start date to date of disease progression or date of death. Patients without documented PD are censored on date of last radiologic assessment.","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Days"}